# Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

> **NCT00687609** · PHASE4 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 7 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Cannabis Abuse

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00687609
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited.
- **Last updated:** 2010-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687609, "Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00687609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*